Merck KGaA (MRK) Given a €95.00 Price Target at JPMorgan Chase & Co.

Merck KGaA (FRA:MRK) has been assigned a €95.00 ($113.10) price target by equities research analysts at JPMorgan Chase & Co. in a note issued to investors on Wednesday. The brokerage presently has a “neutral” rating on the healthcare company’s stock. JPMorgan Chase & Co.’s price target suggests a potential upside of 3.58% from the company’s previous close.

A number of other brokerages have also commented on MRK. UBS Group set a €120.00 ($142.86) price target on Merck KGaA and gave the stock a “buy” rating in a research note on Monday. Kepler Capital Markets set a €115.00 ($136.90) price target on Merck KGaA and gave the stock a “buy” rating in a research note on Monday, November 6th. Warburg Research set a €115.00 ($136.90) price target on Merck KGaA and gave the stock a “buy” rating in a research note on Thursday, November 9th. Independent Research set a €103.00 ($122.62) price target on Merck KGaA and gave the stock a “neutral” rating in a research note on Thursday, November 9th. Finally, Berenberg Bank set a €116.00 ($138.10) price target on Merck KGaA and gave the stock a “buy” rating in a research note on Thursday, November 9th. Twelve investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Merck KGaA presently has a consensus rating of “Hold” and an average price target of €107.57 ($128.06).

Shares of Merck KGaA (MRK) opened at €91.72 ($109.19) on Wednesday. Merck KGaA has a 52 week low of €87.33 ($103.96) and a 52 week high of €115.00 ($136.90). The company has a market capitalization of $11,870.00 and a price-to-earnings ratio of 21.48.

WARNING: “Merck KGaA (MRK) Given a €95.00 Price Target at JPMorgan Chase & Co.” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.com-unik.info/2018/01/12/merck-kgaa-mrk-given-a-95-00-price-target-at-jpmorgan-chase-co.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit